TRCT
ANVS icon

Tower Research Capital (TRC)’s Annovis Bio ANVS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-944
Closed -$2.1K – 5197
2026
Q1 		$2.1K Sell
944
-12,718
-93% -$34.9K ﹤0.01% 4543
2025
Q4 		$47.3K Buy
13,662
+12,641
+1,238% +$38K ﹤0.01% 2463
2025
Q3 		$2.11K Buy
+1,021
New +$2.55K ﹤0.01% 4681
2025
Q2 		– Sell
-1,784
Closed -$2.68K – 5245
2025
Q1 		$2.68K Buy
1,784
+16
+0.9% +$49 ﹤0.01% 4517
2024
Q4 		$8.89K Sell
1,768
-1,319
-43% -$9.55K ﹤0.01% 3958
2024
Q3 		$24.9K Sell
3,087
-3,771
-55% -$35.3K ﹤0.01% 3110
2024
Q2 		$39.5K Buy
6,858
+2,060
+43% +$16.7K ﹤0.01% 3276
2024
Q1 		$57.1K Buy
4,798
+4,376
+1,037% +$47.7K ﹤0.01% 2182
2023
Q4 		$7.89K Sell
422
-220
-34% -$1.95K ﹤0.01% 4566
2023
Q3 		$6.09K Buy
642
+123
+24% +$1.52K ﹤0.01% 4645
2023
Q2 		$7.42K Sell
519
-2,042
-80% -$28.9K ﹤0.01% 4576
2023
Q1 		$39K Buy
2,561
+1,036
+68% +$16.7K ﹤0.01% 2722
2022
Q4 		$21K Sell
1,525
-165
-10% -$2.06K ﹤0.01% 3074
2022
Q3 		$23K Buy
+1,690
New +$22.2K ﹤0.01% 3803
2022
Q1 		– Sell
-669
Closed -$12K – 6062
2021
Q4 		$12K Buy
669
+442
+195% +$11.4K ﹤0.01% 4254
2021
Q3 		$7K Buy
+227
New +$13.1K ﹤0.01% 4621
2021
Q2 		– Sell
-2,259
Closed -$63K – 5440
2021
Q1 		$63K Buy
2,259
+1,481
+190% +$31.7K ﹤0.01% 2924
2020
Q4 		$6K Sell
778
-458
-37% -$2.48K ﹤0.01% 4528
2020
Q3 		$6K Buy
1,236
+208
+20% +$1.11K ﹤0.01% 4276
2020
Q2 		$4K Buy
+1,028
New +$4.25K ﹤0.01% 4327

Other funds holding ANVS

EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Tower Research Capital (TRC)'s ANVS Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Annovis Bio (ANVS) in Q2 2026, closing a stake of 944 shares — an estimated $2.1K sold.

Tower Research Capital (TRC) first reported a position in ANVS in Q2 2020 and held it in 20 quarters. The position peaked at $63K in Q1 2021. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Annovis Bio position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 944 Annovis Bio shares in Q2 2026, an estimated $2.1K.
  • Tower Research Capital (TRC) first reported a position in Annovis Bio in Q2 2020 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s Annovis Bio position peaked at $63K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.